U.S., May 27 -- ClinicalTrials.gov registry received information related to the study (NCT07606391) titled 'Polidocanol 1% and Steroid in Keloids and Hypertrophic Scars' on May 13.
Brief Summary: we will inject intralesional polidocanol 1% in keloids and hypertrophic scars to decrease vascularity and decrease size of lesion compared to intralesional steroid as standard treatment line
Study Start Date: Aug. 01, 2026
Study Type: INTERVENTIONAL
Condition:
Keloid and Hypertrophic Scars
Intervention:
DRUG: Group 1 (polidocanol 1% group):
Patients will receive polidocanol 1 %, a maximum of one milliliter of polidocanol 1% will be injected in each lesion using an insulin syringe with a 24-gauge needle.3- The active substance will be inject...